Clinical trials: Hepatitis E Infection
Hepatitis C, Chronic
Interferon α 2b Pharmacovigilance Study
Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological…
- Trial name
- NCT01841775
- Testing
- interferon α 2b + ribavirin
- Where
- 2 sites in Brazil
- Volunteers
- 85 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04023721
- Testing
- Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors
- Where
- 7 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- F-star Therapeutics, Inc.
Hepatitis E
Prevalence of Hepatitis E During Follow-up Liver and Kidney Transplant Patients in Guadeloupe, French West Indies
Hepatitis E is well known to be a common cause of severe hepatitis on organ-transplanted people. However, several studies also show a risk of transition to a chronic state.
- Trial name
- KARU-HEP (NCT07729202)
- Testing
- Liver and Kidney transplanted patients
- Where
- Guadeloupe
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.
- Trial name
- NCT02570191
- Testing
- Peginterferon alfa-2a
- Where
- 8 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Acute on Chronic Hepatic Failure, Liver Failure
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by an acute and rapid deterioration of liver function in a patient with previously well-compensated liver disease owing to the effects of a…
- Conditions
- Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis E Infection
- Trial name
- HEVRibavirin (NCT01698723)
- Testing
- Ribavirin
- Where
- 2 sites in India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
This phase IV clinical study was designed to evaluate the safety and immunogenicity of the recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 65 years of…
- Trial name
- NCT02417597
- Testing
- Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Chronic Hepatitis B
Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy
This study evaluates whether Peg-IFN alfa-2a can reduce the recurrence rate of hepatitis B in 96 weeks after nucleoside analogue (NUC) withdrawal.
- Trial name
- NCT02594293
- Testing
- PegIFN alfa-2a
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Huashan Hospital
Hepatitis E
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
This is a HEV seroprevalence in the health donors in the Canton Ticino study. The pre-donation sampling pouch of each blood donor coming form the Cantone Ticino region will be collected and tested for HEV serology (IgM and IgG).
- Trial name
- NCT03601221
- Testing
- Sample collection
- Where
- Switzerland
- Volunteers
- 1,447 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Chronic Hepatitis B
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
- Trial name
- NCT00037622
- Testing
- ACH-126, 443 (beta-L-Fd4C)
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Hepatitis B
Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients
Patients with chronic hepatitis B constantly produce the virus in the body. The disease of chronic hepatitis B is the body responding to the virus. Use of steroids can adjust this response.
- Trial name
- NCT00715715
- Testing
- Prednisone Priming
- Where
- United States
- Sponsor
- Maimonides Medical Center
Hepatitis E
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）
The purpose of this study is to determine the safety and immunogenicity of the recombinant hepatitis E vaccine in people older than 65 years, and evaluate the efficacy of hepatitis E vaccine in this population.
- Trial name
- NCT02189603
- Testing
- Recombinant (E. Coli) Hepatitis E Vaccine
- Where
- China
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Hepatitis E Infection
Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women
This is a phase II randomized, observer-blinded, placebo-controlled study with 3 arms enrolling a total of 2,358 participants. The arms are composed of Arm 1, pregnant participants receiving Hecolin® (N=1,104) with immunogenicity…
- Trial name
- NCT05808166
- Testing
- Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli))., Isotonic Sodium Chloride injection
- Where
- Pakistan
- Volunteers
- 2,358 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Hepatitis, Cytokines
Role of Cytokines in Hepatitis E Virus Infection During Pregnancy
Hepatitis E virus is a public health problem in several countries of the world where safe drinking water is a problem. HEV is an exclusive cause of epidemic hepatitis in general population.
- Conditions
- Hepatitis, Cytokines, Pregnancy
- Trial name
- NCT01062321
- Where
- India
- Volunteers
- 491 people, healthy volunteers welcome
- Sponsor
- Maulana Azad Medical College
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin®.
- Trial name
- NCT03365921
- Testing
- Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Chronic Hepatitis B
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B
Currently, seven medications are approved for the treatment of hepatitis B: two formulations of interferon and five nucleons(t)ide analogues.
- Trial name
- NCT01906580
- Testing
- Peg-IFNα-2a, Entecavir
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Beijing 302 Hospital
Hepatitis E Virus Infection
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses…
- Trial name
- NCT06306196
- Testing
- Hecolin® Recombinant Hepatitis E Vaccine, Isotonic Sodium Chloride injection
- Where
- 3 sites in South Africa
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Hepatitis E
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
This test-negative study is designed to evaluate the long-term effectiveness of hepatitis E vaccine (Hecolin®) and to explore the prevalence of rat hepatitis E in Dongtai City.
- Trial name
- NCT05976594
- Testing
- serology and virology detection of hepatitis E virus
- Where
- China
- Volunteers
- 2,900 people
- Sponsor
- Xiamen University
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604212
- Testing
- ARC-520, entecavir, antihistamine
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis B
Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B
Currently, there are several antiviral treatments effective for suppression of viral replication but still failed to cure HBV infection in patients with chronic hepatitis B (CHB).
- Trial name
- NCT01925820
- Testing
- Pegasys&Entecavir
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital